A multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events (MACEs) in patients (pts) with prostate cancer (pc) and cardiovascular disease (CVD) receiving degarelix (GnRH receptor antagonist) or leuprolide (GnRH receptor agonist).
Publication
, Conference
Slovin, SF; Melloni, C; Mansor-Lefebvre, S; Neijber, A; Roe, M
Published in: Journal of Clinical Oncology
May 20, 2018
Duke Scholars
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2018
Volume
36
Issue
15_suppl
Start / End Page
TPS5101 / TPS5101
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Slovin, S. F., Melloni, C., Mansor-Lefebvre, S., Neijber, A., & Roe, M. (2018). A multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events (MACEs) in patients (pts) with prostate cancer (pc) and cardiovascular disease (CVD) receiving degarelix (GnRH receptor antagonist) or leuprolide (GnRH receptor agonist). In Journal of Clinical Oncology (Vol. 36, pp. TPS5101–TPS5101). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.tps5101
Slovin, Susan F., Chiara Melloni, Samreen Mansor-Lefebvre, Anders Neijber, and Matthew Roe. “A multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events (MACEs) in patients (pts) with prostate cancer (pc) and cardiovascular disease (CVD) receiving degarelix (GnRH receptor antagonist) or leuprolide (GnRH receptor agonist).” In Journal of Clinical Oncology, 36:TPS5101–TPS5101. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.tps5101.
Slovin SF, Melloni C, Mansor-Lefebvre S, Neijber A, Roe M. A multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events (MACEs) in patients (pts) with prostate cancer (pc) and cardiovascular disease (CVD) receiving degarelix (GnRH receptor antagonist) or leuprolide (GnRH receptor agonist). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. TPS5101–TPS5101.
Slovin, Susan F., et al. “A multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events (MACEs) in patients (pts) with prostate cancer (pc) and cardiovascular disease (CVD) receiving degarelix (GnRH receptor antagonist) or leuprolide (GnRH receptor agonist).” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. TPS5101–TPS5101. Crossref, doi:10.1200/jco.2018.36.15_suppl.tps5101.
Slovin SF, Melloni C, Mansor-Lefebvre S, Neijber A, Roe M. A multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events (MACEs) in patients (pts) with prostate cancer (pc) and cardiovascular disease (CVD) receiving degarelix (GnRH receptor antagonist) or leuprolide (GnRH receptor agonist). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. TPS5101–TPS5101.
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2018
Volume
36
Issue
15_suppl
Start / End Page
TPS5101 / TPS5101
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences